Arnold & Porter Advises Pfizer Inc. in $1 Billion Transaction of Early-Stage Rare Disease Gene Therapy Portfolio

Arnold & Porter represented client Pfizer in an agreement to sell its early-stage rare disease gene therapy portfolio to Alexion, AstraZeneca Rare Disease.

The transaction, valued at up to $1 billion, involves the transfer of Pfizer's novel adeno-associated virus (AAV) capsids, an innovative tool vital to transferring therapeutic genes to patients.

The deal aligns with Pfizer's commitment to advancing medical innovation and collaboration to enhance the lives of individuals with rare genetic disorders. It is expected to close in Q3 2023.

The Arnold & Porter team was led by partner Lowell Dashefsky and senior associate Tom Wilson, and included partners David Menchel, Laurie Abramowitz, Jennifer Perkins, Matthew Tabas, and Niels Ersbøll, senior associates Ethan Zausner, Reuven Graber, Lazarinka Naydenova, Alyssa Hogan, and associates John Thomas and Alexus Williams.